en · de · es · fr · pt
selank-notes.peptides9000.com › Faq › Selank Background And Peptide Chemistry — Evidence Review

Selank Background And Peptide Chemistry — Evidence Review

By Editorial Desk · published 2026-04-25 · last reviewed 2026-06-01 · Faq

A practical reference on peptidase: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2026-06-01. Anything still debated is marked as such rather than presented as settled.

Selank Background and Peptide Chemistry

Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.

Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.

Analytical Methods and Material Handling

Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.

Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.

Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.

Selank at a glance

PropertyValueNotes
Molecular formulaC33H57N11O9Derived from the seven-residue sequence
Molecular weightAbout 751.9 g/molAverage mass; the monoisotopic value is slightly lower
Residue countSeven amino acidsThr-Lys-Pro-Arg-Pro-Gly-Pro
Parent compoundTuftsin (Thr-Lys-Pro-Arg)Selank extends tuftsin at the C-terminus
Compound classSynthetic short peptideStudied in a research setting; not a licensed drug in most markets

Background and Peptide Identity

Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.

Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.

Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.

Related pages on this site

Mechanism and Evidence Status

Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.

Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.

Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.

Proposed Mechanisms and Research Endpoints

Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.

Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.

Notes from published material

==== 2006–2011: Stadium move and transition ==== In the summer of 2006, Wenger oversaw Arsenal's relocation to the Emirates Stadium. During the construction phase, he described the move as "vital" to the club's financial future and believed Arsenal were better able to attract the best players. Moving to the new stadium, however, presented several problems in the short term, as the club prioritised financing it over the team. Wenger sold some of his experienced players such as Campbell, Lauren and Pires, sanctioned Cole's move to Chelsea in part exchange for defender William Gallas, and integrated young players like Theo Walcott and Alex Song into the first team. His youthful team contested the League Cup final in February 2007 and were the youngest to play in a major English cup final, averaging 21 years. They ultimately came up short against Chelsea, who won the match 2–1. Arsenal finished fourth in the 2006–07 league season; Wenger had ruled out their title chances following defeat to Bolton in November 2006. The team's lack of directness and efficiency of possession was a familiar theme during the campaign; Guardian journalist Daniel Taylor observed two matches into the league season: "The most watchable side are frequently the most frustrating. Arsenal are wonderfully incisive yet infuriatingly blunt."

In 2004, the US decided to grant Major non-NATO ally (MNNA) status to Pakistan. The US extended the MNNA strategic working relationship to India but the offer was turned down. After the September 11 attacks against the US in 2001, President George W. Bush collaborated closely with India in controlling and policing the strategically critical Indian Ocean sea lanes from the Suez Canal to Singapore.

== Medical uses == Arsenic trioxide has emerged as a therapeutic agent in cancer treatment, especially for acute promyelocytic leukemia (APL). It achieves high remission rates, including among patients with relapsed disease, and offering advantages over other treatments like bone marrow transplantation and all-trans retinoic acid (ATRA), particularly by reducing toxicity and improving patient outcomes. The combined regimen of arsenic trioxide with ATRA is now considered a standard of care for newly diagnosed and relapsed APL, showing substantial efficacy even in pediatric and elderly populations. Arsenic trioxide is intended for the induction of remission and consolidation in adult patients with acute promyelocytic leukemia who have the t(15;17) translocation and/or the fusion of PML and RARα genes. The drug should be used after treatment failure or relapse. Prior therapy should include retinoid and chemotherapy. The current standard of care for acute promyelocytic leukemia (APL) is risk-adapted therapy based on the patient’s white blood cell count at diagnosis. For patients with non-high-risk APL (typically defined as a white blood cell count ≤10,000/μL), the preferred treatment is a chemotherapy-free regimen that combines all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), which has demonstrated superior efficacy and a favorable safety profile compared to regimens that include chemotherapy.

Sources: en.wikipedia.org

Background from the literature

=== Meningitis === Blood procalcitonin levels can help confirm bacterial meningitis and, if negative, can effectively rule out bacterial meningitis. This was shown in a review of over 2000 patients in which PCT had a sensitivity of 86% and a specificity of 80% for cerebrospinal fluid PCT. Blood PCT measurements proved superior to cerebrospinal fluid PCT with a sensitivity of 95% and a specificity of 97% as a marker for bacterial meningitis. In acute meningitis, serum PCT is useful as a biomarker for sepsis. It can also be of use in determining viral meningitis versus bacterial meningitis. These findings are the result of a 2018 literature review. This followed a 2015 meta analysis that showed that PCT had a sensitivity of 90% and a specificity of 98% in judging viral versus bacterial meningitis. PCT also outperformed other biomarkers such as C-reactive protein.

== References == Crowl, Philip A. (1995). The Pacific War: Campaign in the Marianas. United States Army in World War II. United States Army Center of Military History. ISBN 978-0-16-089915-7. LCCN 60-60000. Archived from the original on 21 July 2022. Retrieved 10 February 2017. Hoyt, Edwin Palmer (1986). Japan's War: The Great Pacific Conflict, 1853 to 1952. New York: McGraw-Hill. ISBN 0-07-030612-5. Morison, Samuel Eliot (1953). New Guinea and the Marianas, March 1944 – August 1944. History of United States Naval Operations in World War II. Vol. VIII. Little, Brown and Company. Polmar, Norman (2008). Aircraft Carriers: A History of Carrier Aviation and Its Influence on World Events, 1946–2006. Vol. II. Washington, D.C.: Potomac Books. pp. 377–400. ISBN 978-1-57488-665-8. Archived from the original on 21 July 2022. Retrieved 1 June 2014. Potter, E. B. (1990). Admiral Arleigh Burke. Naval Institute Press. ISBN 978-1-59114-692-6. Roscoe, Theodore (1949). Pig Boats. New York: Bantam Books. ISBN 978-0-553-13040-4. {{cite book}}: ISBN / Date incompatibility (help) Shaw, Henry I. Jr.; Nalty, Bernard C.; Turnbladh, Edwin T. (1966). "Strategic Victory in the Marianas Liberation of Guam; Capture of Saipan and Tinian". Central Pacific Drive (PDF). History of U.S. Marine Corps Operations in World War II. Vol. III. Historical Branch, G-3 Division, Headquarters, U.S. Marine Corps. Archived (PDF) from the original on 26 January 2021. Retrieved 25 November 2020. Shores, Christopher (1985). Duel for the Sky: Ten Crucial Battles of World War II. London: Grub Street. ISBN 978-0-7137-1601-6.

Recirculating aquaculture systems (RAS) recycle water by circulating it through filters to remove fish waste and food, and then recirculating it back into the tanks. This saves water, and the waste gathered can be used in compost or, in some cases, could even be treated and used on land. While RAS was developed with freshwater fish in mind, scientists associated with the Agricultural Research Service have found a way to rear saltwater fish using RAS in low-salinity waters. Although saltwater fish are raised in offshore cages or caught with nets in water that typically has a salinity of 35 parts per thousand (ppt), scientists were able to produce healthy pompano, a saltwater fish, in tanks with a salinity of only 5 ppt. Commercializing low-salinity RAS is predicted to have positive environmental and economic effects. Unwanted nutrients from the fish food would not be added to the ocean, and the risk of transmitting diseases between wild and farm-raised fish would be greatly reduced. The price of expensive saltwater fish, such as the pompano and cobia used in the experiments, would be reduced. However, before any of this can be done researchers must study every aspect of the fish's lifecycle, including the amount of ammonia and nitrate the fish will tolerate in the water, what to feed the fish during each stage of its lifecycle, the stocking rate that will produce the healthiest fish, etc. Some 16 countries now use geothermal energy for aquaculture, including China, Israel, and the United States.

The French army peaked in size in the 1790s with 1.5 million Frenchmen enlisted although battlefield strength was much less. Haphazard bookkeeping, rudimentary medical support and lax recruitment standards ensured that many soldiers either never existed, fell ill or were unable to withstand the physical demands of soldiering. About 2.8 million Frenchmen fought on land and about 150,000 at sea, bringing the total for France to almost 3 million combatants during almost 25 years of warfare.

Sources: en.wikipedia.org

Reference notes

Another champion of the approach of developing chemical analogues of known active substances was Sir David Jack at Allen and Hanbury's, later Glaxo, who pioneered the first inhaled selective beta2-adrenergic agonist for asthma, the first inhaled steroid for asthma, ranitidine as a successor to cimetidine, and supported the development of the triptans. Gertrude Elion, working mostly with a group of fewer than 50 people on purine analogues, contributed to the discovery of the first anti-viral; the first immunosuppressant (azathioprine) that allowed human organ transplantation; the first drug to induce remission of childhood leukemia; pivotal anti-cancer treatments; an anti-malarial; an anti-bacterial; and a treatment for gout. Cloning of human proteins made possible the screening of large libraries of compounds against specific targets thought to be linked to specific diseases. This approach is known as reverse pharmacology and is the most frequently used approach today. In the 2020s, qubit and quantum computing started to be used to reduce the time needed to drug discovery.

Vancomycin biosynthesis occurs primarily via three nonribosomal protein syntheses (NRPSs) VpsA, VpsB, and VpsC. The enzymes determine the amino acid sequence during its assembly through its 7 modules. Before vancomycin is assembled through NRPS, the non-proteinogenic amino acids are first synthesized. L-tyrosine is modified to become the β-hydroxytyrosine (β-HT) and 4-hydroxyphenylglycine (4-Hpg) residues. 3,5-dihydroxyphenylglycine ring (3,5-DPG) is derived from acetate.

== Role of smoking == To date, all reported patients with SRIF have been heavy current smokers or ex-smokers, lending credence to the assertion that this condition is caused by smoking. There are no published reports of SRIF in never-smokers.

=== In plants === Phenylalanine is the starting compound used in the synthesis of flavonoids. Lignan is derived from phenylalanine and tyrosine. Phenylalanine is converted to cinnamic acid by the enzyme phenylalanine ammonia-lyase.

== History == Pentamidine was first used to treat African trypanosomiasis in 1937 and leishmaniasis in 1940 before it was registered as pentamidine mesylate in 1950. The sudden increase in requests for use of pentamidine isethionate in then unlicensed form from the CDC in the early 1980s for treating Pneumocystis jirovecii in young male patients was key in identifying the emergence of the HIV/AIDS epidemic at that time. Its efficacy against Pneumocystis jirovecii was demonstrated in 1987, following its re-emergence on the drug market in 1984 in the current isethionate form.

Sources: en.wikipedia.org

Frequently asked questions

What is selank?

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.

How does selank differ from tuftsin?

Tuftsin contains four residues, while selank carries an additional Pro-Gly-Pro segment at the carboxyl end. That extension is intended to reduce enzymatic cleavage. Comparative pharmacokinetic data in humans remain limited.

Is the mechanism of action established?

No single receptor target is widely accepted as the definitive mediator of the reported effects. Proposed contributors include GABAergic modulation, shifts in monoamine turnover, and altered neuropeptide degradation. The mechanism is treated in the literature as unresolved.

How is purity determined?

Purity is usually reported as an HPLC area percentage, most often measured at 214 nm. Identity is confirmed separately by mass spectrometry. A certificate of analysis should state both the method and the observed value.

Network